JP2015516984A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015516984A5 JP2015516984A5 JP2015509172A JP2015509172A JP2015516984A5 JP 2015516984 A5 JP2015516984 A5 JP 2015516984A5 JP 2015509172 A JP2015509172 A JP 2015509172A JP 2015509172 A JP2015509172 A JP 2015509172A JP 2015516984 A5 JP2015516984 A5 JP 2015516984A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antibody fragment
- cell
- animal
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638834P | 2012-04-26 | 2012-04-26 | |
| US61/638,834 | 2012-04-26 | ||
| PCT/US2013/038370 WO2013163519A1 (en) | 2012-04-26 | 2013-04-26 | Anti-cd22 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015516984A JP2015516984A (ja) | 2015-06-18 |
| JP2015516984A5 true JP2015516984A5 (enExample) | 2016-10-13 |
Family
ID=49483918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509172A Pending JP2015516984A (ja) | 2012-04-26 | 2013-04-26 | 抗ｃｄ２２抗体 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9856323B2 (enExample) |
| EP (1) | EP2841459A4 (enExample) |
| JP (1) | JP2015516984A (enExample) |
| KR (1) | KR20150008080A (enExample) |
| CN (1) | CN104428316A (enExample) |
| AU (2) | AU2013251482B2 (enExample) |
| BR (1) | BR112014026744A8 (enExample) |
| CA (1) | CA2871764A1 (enExample) |
| HK (1) | HK1207653A1 (enExample) |
| MX (1) | MX361533B (enExample) |
| RU (1) | RU2014147452A (enExample) |
| WO (1) | WO2013163519A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014057118A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
| GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
| GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
| GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
| GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| MX2020006494A (es) | 2017-12-22 | 2020-11-24 | Teneobio Inc | Anticuerpos de cadena pesada que se unen a cd22. |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| CN119564852A (zh) | 2019-06-14 | 2025-03-07 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| WO2021083467A1 (en) * | 2019-10-28 | 2021-05-06 | Y-Mabs Therapeutics, Inc. | Administration of cd22, cd33 and/or tim-3 antibodies using ommaya reservoirs for the treatment of cns cancer or neurodegenerative diseases |
| AU2021250615A1 (en) * | 2020-04-02 | 2022-12-01 | Nanjing IASO Biotechnology Co., Ltd. | Fully human anti-human CD22 chimeric antigen receptor and application thereof |
| CN113527507A (zh) | 2020-04-16 | 2021-10-22 | 上海赛比曼生物科技有限公司 | 靶向cd22的嵌合抗原受体及其制法和应用 |
| CA3180138A1 (en) * | 2020-06-12 | 2021-12-16 | Ichnos Sciences SA | Antibody formulation diluent |
| CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
| EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
| TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE306930T1 (de) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
| WO2003074679A2 (en) * | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
| GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
| US8389688B2 (en) * | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| HRP20140172T1 (hr) | 2006-05-30 | 2014-03-28 | Genentech, Inc. | Protutijela i imunokonjugati kao i njihove uporabe |
| CN103172743B (zh) * | 2006-12-01 | 2015-04-08 | 梅达雷克斯有限责任公司 | 结合cd22的人抗体及其用途 |
| WO2014057118A1 (en) * | 2012-10-12 | 2014-04-17 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
-
2013
- 2013-04-26 RU RU2014147452A patent/RU2014147452A/ru not_active Application Discontinuation
- 2013-04-26 KR KR20147030515A patent/KR20150008080A/ko not_active Ceased
- 2013-04-26 US US14/396,869 patent/US9856323B2/en not_active Expired - Fee Related
- 2013-04-26 MX MX2014012977A patent/MX361533B/es active IP Right Grant
- 2013-04-26 HK HK15108288.7A patent/HK1207653A1/xx unknown
- 2013-04-26 JP JP2015509172A patent/JP2015516984A/ja active Pending
- 2013-04-26 WO PCT/US2013/038370 patent/WO2013163519A1/en not_active Ceased
- 2013-04-26 EP EP13781426.5A patent/EP2841459A4/en not_active Withdrawn
- 2013-04-26 CA CA2871764A patent/CA2871764A1/en not_active Abandoned
- 2013-04-26 BR BR112014026744A patent/BR112014026744A8/pt not_active Application Discontinuation
- 2013-04-26 AU AU2013251482A patent/AU2013251482B2/en not_active Ceased
- 2013-04-26 CN CN201380022320.0A patent/CN104428316A/zh active Pending
-
2017
- 2017-12-04 AU AU2017268687A patent/AU2017268687A1/en not_active Abandoned
- 2017-12-11 US US15/837,944 patent/US20180086843A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015516984A5 (enExample) | ||
| US9828435B2 (en) | Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency | |
| US20240252673A1 (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer | |
| CN114555123A (zh) | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 | |
| JP2013543498A5 (enExample) | ||
| RU2014147452A (ru) | Анти-cd22 антитела | |
| RU2007133108A (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ | |
| EP3188758A1 (en) | Sirp alpha-antibody fusion proteins | |
| NL2024544B1 (en) | Compositions And Methods For Cancer Therapy | |
| JP2019534705A (ja) | 抗ｉｌ１−ｒａｐ抗体 | |
| RU2014120577A (ru) | Моноклональное антитело cd44 для лечения b-клеточной хронической лимфоцитарной лейкемии и других гематологических злокачественных заболеваний | |
| JP2014515600A5 (enExample) | ||
| JP2011504092A5 (enExample) | ||
| AU2021315882A1 (en) | Compositions including ex vivo armed T cells with multi-specific antibodies and uses thereof | |
| JP2020523414A (ja) | Ｌｇｒ５に結合する抗体薬物複合体 | |
| KR20250007062A (ko) | Epo 수용체 효능제 및 길항제 | |
| CN114616245B (zh) | 一种抗cd38的抗体及其用途 | |
| TW202409088A (zh) | 抗lilrb2抗體及其用途 | |
| TW202126697A (zh) | 個人化癌症免疫治療 | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| CN118524843A (zh) | B细胞恶性肿瘤的治疗 | |
| WO2025006507A1 (en) | Oncology combination therapy and methods of use | |
| WO2025081059A1 (en) | Carriers for drug conjugates | |
| WO2025151374A1 (en) | Oncology combination therapy and methods of use | |
| CN119677544A (zh) | B细胞特异性mab-sirna缀合物改善肌无力 |